These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 28823022)

  • 21. Osteogenesis imperfecta: practical treatment guidelines.
    Antoniazzi F; Mottes M; Fraschini P; Brunelli PC; Tatò L
    Paediatr Drugs; 2000; 2(6):465-88. PubMed ID: 11127846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteogenesis Imperfecta: update on presentation and management.
    Cheung MS; Glorieux FH
    Rev Endocr Metab Disord; 2008 Jun; 9(2):153-60. PubMed ID: 18404382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
    Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteogenesis imperfecta, current and future medical treatment.
    Rauch F; Glorieux FH
    Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review.
    Castillo H; Samson-Fang L;
    Dev Med Child Neurol; 2009 Jan; 51(1):17-29. PubMed ID: 19087101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the Classification and Treatment of Osteogenesis Imperfecta.
    Thomas IH; DiMeglio LA
    Curr Osteoporos Rep; 2016 Feb; 14(1):1-9. PubMed ID: 26861807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of an interdisciplinary approach in the healing of long bone fractures in patients with osteogenesis imperfecta].
    Kokavec M; Novorolský K; Pribilincová Z
    Acta Chir Orthop Traumatol Cech; 2008 Jun; 75(3):185-9. PubMed ID: 18601816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of atypical femoral fracture in a patient with osteogenesis imperfecta.
    Tan JY; Seow CJ
    BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29269360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mid-term Results of Femoral and Tibial Osteotomies and Fassier-Duval Nailing in Children With Osteogenesis Imperfecta.
    Azzam KA; Rush ET; Burke BR; Nabower AM; Esposito PW
    J Pediatr Orthop; 2018 Jul; 38(6):331-336. PubMed ID: 27379783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X.
    Song Y; Zhao D; Xu X; Lv F; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
    Osteoporos Int; 2018 Jun; 29(6):1389-1396. PubMed ID: 29520608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta.
    Garganta MD; Jaser SS; Lazow MA; Schoenecker JG; Cobry E; Hays SR; Simmons JH
    BMC Musculoskelet Disord; 2018 Sep; 19(1):344. PubMed ID: 30249227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zolendronate in osteogenesis imperfecta.
    Panigrahi I; Das RR; Marwaha RK
    J Pediatr Endocrinol Metab; 2009 Aug; 22(8):763. PubMed ID: 19845128
    [No Abstract]   [Full Text] [Related]  

  • 35. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoledronic acid treatment in children with osteogenesis imperfecta.
    Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
    Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of bisphosphonates in children with osteogenesis imperfecta.
    Glorieux FH
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1491-5. PubMed ID: 11837505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen.
    Biggin A; Briody JN; Ormshaw E; Wong KK; Bennetts BH; Munns CF
    Horm Res Paediatr; 2014; 81(3):204-10. PubMed ID: 24356182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.
    Trejo P; Fassier F; Glorieux FH; Rauch F
    J Bone Miner Res; 2017 May; 32(5):1034-1039. PubMed ID: 28019684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.